Singhal T. A review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatrics/Indian J Pediatr. 2020;87(4):281–6. https://doi.org/10.1007/s12098-020-03263-6.

Article  Google Scholar 

Anand U, Cabreros C, Mal J, Ballesteros F, Sillanpää M, Tripathi V, et al. Novel coronavirus disease 2019 (COVID-19) pandemic: from transmission to control with an interdisciplinary vision. Environ Res. 2021;197:111126. https://doi.org/10.1016/j.envres.2021.111126.

Article  CAS  Google Scholar 

Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. New Engl J Medicine/˜the œNew Engl J Med. 2020;382(10):970–1. https://doi.org/10.1056/nejmc2001468.

Article  Google Scholar 

Callaway E. Had COVID? You’ll probably make antibodies for a lifetime. Nature. 2021. https://doi.org/10.1038/d41586-021-01442-9.

Article  Google Scholar 

Marchi S, Viviani S, Remarque EJ, Ruello A, Bombardieri E, Bollati V, et al. Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. PLoS ONE. 2021;16(7):e0253977. https://doi.org/10.1371/journal.pone.0253977.

Article  CAS  Google Scholar 

Amellal H, Assaid N, Charoute H, Akarid K, Maaroufi A, Ezzikouri S, et al. Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: a prospective longitudinal study. PLoS ONE. 2023;18(7):e0288557. https://doi.org/10.1371/journal.pone.0288557.

Article  CAS  Google Scholar 

Ma H, Zeng W, He H, Zhao D, Dehua J, Zhou P, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunology/Cellular Mol Immunol. 2020;17(7):773–5. https://doi.org/10.1038/s41423-020-0474-z.

Article  CAS  Google Scholar 

Efrati S, Catalogna M, Hamed RA, Hadanny A, Bar-Chaim A, Benveniste‐Levkovitz P, et al. Early and long-term antibody kinetics of asymptomatic and mild disease COVID-19 patients. Sci Rep. 2021;11(1). https://doi.org/10.1038/s41598-021-93175-y.

Forthal DN. Functions of antibodies. Microbiol Spectr. 2014;2(4):1–17. PMID: 25215264; PMCID: PMC4159104.

Article  Google Scholar 

Marta RA, Nakamura GEK, De Matos Aquino B, Bignardi PR. COVID-19 vaccines: update of the vaccines in use and under development. Vacunas. 2022;23:S88–102. https://doi.org/10.1016/j.vacun.2022.06.003.

Article  CAS  Google Scholar 

Deng S, Liang H, Chen P, Li Y, Li Z, Fan S, et al. Viral Vector Vaccine Development and Application during the COVID-19 pandemic. Microorganisms. 2022;10(7):1450. https://doi.org/10.3390/microorganisms10071450.

Article  CAS  Google Scholar 

Song SK, Lee DH, Nam JH, Kim YH, Suk JS, Kang DW, et al. IgG seroprevalence of COVID-19 among individuals without a history of the Coronavirus Disease infection in Daegu, Korea. J Korean Med Sci. 2020;35(29). https://doi.org/10.3346/jkms.2020.35.e269.

Vassallo RR, Dumont LJ, Bravo M, Hazegh K, Kamel H. Progression and predictors of SARS-COV-2 antibody seroreactivity in US blood donors. Transfus Med Rev. 2021;35(3):8–15. https://doi.org/10.1016/j.tmrv.2021.07.003.

Article  Google Scholar 

Murhekar M, Bhatnagar T, Selvaraju S, Rade K, Velusamy S, Thangaraj JWV, et al. Prevalence of SARS-CoV-2 infection in India: findings from the national serosurvey, May-June 2020. Indian J Med Res. 2020;152(1):48. https://doi.org/10.4103/ijmr.ijmr_3290_20.

Article  CAS  Google Scholar 

Murhekar M, Bhatnagar T, Selvaraju S, Velusamy S, Thangaraj JWV, Shah NK, et al. SARS-CoV-2 antibody seroprevalence in India, August–September 2020: findings from the second nationwide household serosurvey. ˜the œLancet Global Health/˜the œLancet Global Health. 2021;9(3):e257–66. https://doi.org/10.1016/s2214-109x(20)30544-1.

Article  CAS  Google Scholar 

Murhekar M, Bhatnagar T, Thangaraj JWV, Velusamy S, Kumar MS, Selvaraju S, et al. SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021. Int J Infect Dis. 2021;108:145–55. https://doi.org/10.1016/j.ijid.2021.05.040.

Article  CAS  Google Scholar 

Murhekar M, Bhatnagar T, Thangaraj JWV, Velusamy S, Kumar MS, Selvaraju S, et al. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June–July 2021: a population-based cross-sectional study. PLoS Med. 2021;18(12):e1003877. https://doi.org/10.1371/journal.pmed.1003877.

Article  CAS  Google Scholar 

ICMR Guidelines for Good Clinical Laboratory Practices (GCLP), Indian Council of Medical Research. 2021. https://main.icmr.nic.in/hi/guidelines.https://main.icmr.nic.in/sites/default/files/upload_documents/GCLP_Guidelines_2020_Final.pdf Accessed 31 Aug 2024.

Kumar NP, Padmapriyadarsini C, Devi K, Banurekha VV, Nancy A, Kumar CPG, et al. Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: a pilot study. Indian J Med Res. 2021;153(5):671. https://doi.org/10.4103/ijmr.ijmr_2066_21.

Article  CAS  Google Scholar 

Sahay RR, Yadav P, Nandapurkar A, Dhawde R, Suryawanshi A, Patil DY, et al. Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months. Hum Vaccines &Immunotherapeutics. 2022;18(7). https://doi.org/10.1080/21645515.2022.2156753.

Bhuiyan TR, Akhtar M, Khaton F, Rahman S, Ferdous J, Alamgir ASM, et al. Covishield vaccine induces robust immune responses in Bangladeshi adults. IJID Reg. 2022;3:211–7. https://doi.org/10.1016/j.ijregi.2022.04.006.

Article  Google Scholar 

Thomas RE, Sukumaran A, R AK, Thomas T, Edwin BT, Haritha PR, et al. Impact of Covishield vaccination in terms of SARS COV-2 neutralizing antibody expression. Indian J Clin Biochem. 2022;38(1):51–8. https://doi.org/10.1007/s12291-022-01030-2.

Article  CAS  Google Scholar 

Choudhary HR, Parai D, Dash GC, Kshatri JS, Mishra N, Choudhary PK, et al. Persistence of antibodies against spike glycoprotein of SARS-COV-2 in healthcare workers post double dose of BBV-152 and AZD1222 vaccines. Front Med. 2021;8. https://doi.org/10.3389/fmed.2021.778129.

Nanda R, Gupta P, Giri A, Patel S, Shah S, Mohapatra E. Serological evaluation of antibody titers after vaccination against COVID-19 in 18-44-year-old individuals at a tertiary care center. Curēus. 2023. https://doi.org/10.7759/cureus.40543.

Article  Google Scholar 

Madkaikar M, Patil R, Shanbhag S, Shankarkumar A. Antibody profile in post-vaccinated & SARS-CoV-2–infected individuals. Indian J Med Res. 2022. https://doi.org/10.4103/ijmr.ijmr_3330_21. Publish Ahead of Print.

Article  Google Scholar 

Singh AK, Phatak S, Singh R, Bhattacharjee K, Singh N, Gupta A, et al. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield TM®) and BBV-152 (Covaxin TM®) among health care workers in India: the final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine. 2021;39(44):6492–509. https://doi.org/10.1016/j.vaccine.2021.09.055.

Article  CAS  Google Scholar 

Ahmed S, Mehta P, Paul A, Cherian SA, Shenoy S. Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort. Ann Rheum Dis. 2022;81(6):868–74. https://doi.org/10.1136/annrheumdis-2021-221922.

Article  CAS  Google Scholar 

Rakshit S, Babji S, Parthiban C, Madhavan R, Adiga V. Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD TM and COVAXIN® induced immunity in COVID-19 exposed Indians. Npj Vaccines. 2023;8(1). https://doi.org/10.1038/s41541-023-00731-w.

Chen J, Li G, Wu X, Fan Y, Liu M, Li P, et al. BCG-induced trained immunity: history, mechanisms and potential applications. J Translational Med. 2023;21(1). https://doi.org/10.1186/s12967-023-03944-8.

Rakshit S, Adiga V, Ahmed A, Parthiban C, Kumar NC, Dwarkanath P, et al. Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD TM vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults. Front Immunol. 2022;13. https://doi.org/10.3389/fimmu.2022.985938.

Gong W, Aspatwar A, Wang S, Parkkila S, Wu X. COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials. Expert Rev Vaccines. 2021;20(7):857–80. https://doi.org/10.1080/14760584.2021.1938550.

Article  CAS  Google Scholar 

Santos AP, Werneck GL, Dalvi APR, Santos CCD, Tierno PFGMM, Condelo HS, et al. The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2—The results of ProBCG: a multicenter randomized clinical trial in Brazil. Int J Infect Dis. 2023;130:8–16. https://doi.org/10.1016/j.ijid.2023.02.014.

Article  CAS  Google Scholar 

Huang C, Jang T, Wu P, Kuo M, Yeh M, Wang C, et al. Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort. Virol J. 2023;20(1). https://doi.org/10.1186/s12985-023-02056-5.

Ou X, Jiang J, Lin B, Liu Q, Wang L, Chen G, et al. Antibody responses to COVID-19 vaccination in people with obesity: a systematic review and meta‐analysis. Influenza Other Respir Viruses. 2022;17(1). https://doi.org/10.1111/irv.13078.

Ray JG, Park AL. SARS-CoV-2 vaccination, ABO blood group and risk of COVID-19: population-based cohort study. BMJ Open. 2022;12(7):e059944. https://doi.org/10.1136/bmjopen-2021-059944.

Article  Google Scholar 

Žiberna K, Jež M, Jazbec K, Mali P, Potokar UR, Rožman P. ABO blood group does not influence the level of anti-SARS‐CoV‐2 antibodies in convalescent plasma donors. Transfusion. 2022;62(3):556–62. https://doi.org/10.1111/trf.16808.

Article  CAS  Google Scholar 

Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A et al. One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19. ˜the œJournal of Clinical Investigation/˜the œJournal of Clinical Investigation. 2021;131(12). https://doi.org/10.1172/jci149154

Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infectious Diseases/˜the œLancet. Infect Dis. 2022;22(7):1002–10. https://doi.org/10.1016/s1473-3099(22)00146-3.

Article  CAS  Google Scholar 

Zhang S, Xu K, Li C, Zhou L, Kong X, Peng J, et al. Long-term kinetics of SARS-COV-2 antibodies and impact of inactivated vaccine on SARS-COV-2 antibodies based on a COVID-19 patients cohort. Front Immunol. 2022;13. https://doi.org/10.3389/fimmu.2022.829665.

Zhao M, Slotkin R, Sheth AH, Pischel L, Kyriakides TC, Emu B, et al. Serum neutralizing antibody titers 12 months after coronavirus Disease 2019 Messenger RNA vaccination: correlation to clinical variables in an adult, US population. Clinical infectious Diseases/Clinical Infectious diseases. Volume 76. Online University of Chicago; 2022. pp. e391–9. 3https://doi.org/10.1093/cid/ciac416.

Wheeler S, Shurin GV, Yost M, Anderson A, Pinto L, Wells A, et al. Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. Microbiol Spectr. 2021;9(1). https://doi.org/10.1128/spectrum.00341-21.

Ali H, Alahmad B, Alshammari A, Alterki A, Hammad MM, Cherian P, et al. Previous COVID-19 infection and antibody levels after vaccination. Front Public Health. 2021;9. https://doi.org/10.3389/fpubh.2021.778243.

Garofalo E, Biamonte F, Palmieri C, Battaglia AM, Sacco A, Biamonte E, et al. Severe and mild-moderate SARS-CoV-2 vaccinated patients show different frequencies of IFNγ-releasing cells: an exploratory study. PLoS ONE. 2023;18(2):e0281444.